A rapid testing mechanism for respiratory viral pathogens includes a filter material positioned to capture exhaled breath particles from a respiratory tract. A portion of the filter material is impregnated with a pathogen binding adsorptive reagent. When the exhaled breath particles pass through the filter material the following occurs: when the binding adsorptive reagent reacts, a positive test for respiratory viral pathogens is indicated by the filter material; and when pathogen binding adsorptive reagent does not react, a negative test for respiratory viral pathogens is indicated by the filter material.

Disclosed herein are methods for diagnosing or prognosticating SARS-CoV-2 infection and/or COVID-19 in a subject. The methods set forth improved immunoassays, sensing platforms, and methods for detecting SARS-CoV-2 infection and re-infection.

A method for evaluating a biological material for unassociated virus-size particles having a particular epitope uses a fluorescent antibody stain specific for binding with the epitope and a fluid sample with the virus-size particles and fluorescent antibody stain is subjected to flow cytometry with identification of fluorescent emission detection events indicative of passage through a flow cell of a flow cytometer of unassociated labeled particles of virus size including such a virus-size particle and fluorescent antibody stain.

A method for evaluating an antiviral ability of a convalescent plasma by detecting an antibody against RBD of S protein, includes: preparing a convalescent plasma; detecting the antibody against RBD of S protein according to a principle of antigen-antibody specific binding; and evaluating the antiviral ability of the convalescent plasma according to a content of the antibody against RBD in detecting the antibody against RBD of S protein.

Provided is a method and a device for screening an antigen epitope polypeptide. The screening method includes: predicting one or more antigen epitopes with all proteome sequences of a target coronavirus to obtain a predicted epitope region; screening a polypeptide with a differential response to a positive serum sample infected by the target coronavirus and a control serum sample with a polypeptide chip technology, and recording the polypeptide as a differential peptide fragment; comparing the differential peptide fragment with all proteome sequences of the target coronavirus to obtain a first conserved motif region; screening regions meeting epitope screening conditions from the predicted epitope region and the first conserved motif region to obtain the antigen epitope, wherein the epitope screening conditions comprise a non-phosphorylation region and/or an extracellular region of the target coronavirus.

A lateral flow assay and compositions for performing such an assay are described herein that detect whole virus (e.g., HIV, HCV, HSV-2) or viral proteins that use the broad-spectrum anti-viral lectin, griffisthin (GRFT), conjugated to polymeric or gold nanoparticles (NPs) and an appropriate monoclonal antibody (mAb) to confer virus selectivity.

Provided herein are apparatuses, systems, kits, and methods, for detecting a virus contained within human breath or ambient air. The apparatus includes a housing comprising a base and a cover, the base having a sample collection surface, and the cover having a port and substantially enclosing the sample collection surface thereby defining a sample collection chamber. The apparatus includes a tube extending through the port and configured to receive a gaseous sample containing moisture and direct the gaseous sample to the sample collection surface. The apparatus includes a cooling device configured to cool the gaseous sample and thereby condense the moisture on the sample collection surface and a sample collection material disposed on the sample collection surface. The sample collection material is configured to absorb the condensed moisture.

The present disclosure relates to solid dosage forms comprising anti-HCV compounds and methods of using such dosage forms to treat or prevent HCV infection. Direct-acting antiviral agents (DAAs) have a high cure rate, and favorable tolerability in persons infected with hepatitis C virus (HCV). However, shorter courses of therapy can improve adherence, affordability, and increase DAAs accessibility. The addition of an NS3 protease inhibitor to dual NS5A-NS5B (nucleoside) inhibitors enhances antiviral efficacy, and reduces treatment duration to 3 weeks (wks) in individuals with a rapid virologic response (RVR), defined as plasma HCV RNA<500, or <1,000, IU/mL by Day 2 of treatment.

The present disclosure concerns methods of detecting viral respiratory infections by analyzing biomarkers in a viral transport medium sample. In various embodiments the biomarkers are assessed by measuring mRNA or protein. In certain embodiments the biomarkers are nasal-virus induced molecules.

The invention relates to coronavirus peptides, and the use of such peptides for the diagnosis, treatment and prevention of coronavirus infection.